CancerAid is an oncologist-founded company that delivers award-winning technology & personalized coaching to members diagnosed with cancer, in a caregiving capacity or at high risk of a cancer diagnosis.
CancerAid’s differentiators include: 1. Delivering high-value employee support at a time of need, which helps attract and retain employees (incl. at Coca Cola, Aon, Lendlease etc) 2. Demonstrated cost reductions incl. 73% increased likelihood of return to work (published 2021) 3. Delivering proactive organizational support to reduce the burden of cancer CancerAid’s solution is built upon evidence that shows cancer patients who are better educated and supported have fewer treatment discontinuations, use less health system resources, and have better clinical outcomes. Our results include: i) High program satisfaction (+84 NPS) ii) High program utilization (35%) iii) High program engagement (94%) and completion rates (91%) iv) Demonstrated cost savings. incl. 73% more likely to return to work
There are 3 market problems CanderAid is solving: 1. Rising costs from cancer 2. Reducing the burden of cancer on the population 3. Improving the member experience. Research shows that cancer patients who are better educated and supported have fewer treatment discontinuations, use less health system resources, and have better clinical outcomes. For example, patients who track and understand their symptoms of chemotherapy & proactively discuss this with their oncologist or primary care physician experience 17% fewer trips to the emergency room. For most employers and health plans, cancer is a top claim cost. Additionally, the mental and physical impacts of cancer (for both diagnosed employees and caregivers) is a large cost that manifests as mandated support payments, team disruption, absenteeism, loss of productivity and engagement, increased risk of employee depression and anxiety, management stress, & unfilled positions.
i) Employer cost savings: Aung et al. American Society Clinical Oncology 2022. Retrospective cohort analysis with propensity score matching of n=250 that showed a 12.8% absolute increase (73% relative increase) in return to work rates among CancerAid participants compared to controls (non-participants). Lo et al. JMIR CancerAid 2011. Propensity score matching of n=440 that showed returned to work achieved 16.5 weeks sooner among CancerAid participants compared to controls (non-participants). ii) Quality of Life: Seebacher et al. Victoria Comprehensive Cancer Centre 2022. Retrospective analysis n=79 that showed improvements in the frequency of emotional problems (54%) and mental health (54%), level of fatigue (53%), overall quality of life (53%), followed by physical health (51%).
